Published DSIP insomnia studies contain historical intravenous research doses, but they do not establish a standard home subcutaneous dose for sleep. The results are mixed: one small study reported improvement, while other controlled studies found limited clinical benefit. Those differences matter more than copying a microgram schedule from another website.
What doses and routes were actually studied?
| Study | Design and administration | Reported interpretation |
|---|---|---|
| Monti and colleagues, 1987 | Double-blind crossover study in chronic insomnia; 25 nmol/kg intravenously over four nights. | Some sleep measures changed, but several improvements were not significant versus baseline or placebo. The authors judged the improvement of little clinical significance. |
| Schneider-Helmert, 1987 | Fourteen middle-aged people with chronic insomnia; placebo-controlled, double-blind administration over seven successive nights. | The abstract reports improved night sleep and daytime alertness and performance. It does not provide a basis for assigning a home subcutaneous dosing schedule. |
| Bes and colleagues, 1992 | Sixteen people with chronic insomnia; matched-pairs parallel groups. DSIP 25 nmol/kg intravenously on three afternoons was compared with glucose placebo. | Some objective sleep measures improved, but effects were weak and potentially influenced by placebo-group changes. Subjective sleep quality did not improve; the authors did not find major short-term therapeutic benefit. |
These studies used different designs, observation periods and outcome measures. Their findings cannot be reduced to either “DSIP always works” or “there has never been human research.” The relevant question is what each study actually tested and how much confidence it provides.
Why 25 nmol/kg is not the same as 250 micrograms
A nanomole-per-kilogram dose is expressed as an amount of molecules per unit of body weight. A microgram dose is a mass. Converting between them requires the compound's molecular mass and the participant's weight. A flat microgram number cannot be read directly from a nmol/kg value.
The route is a separate variable. An intravenous study does not establish the concentration, absorption or duration of exposure produced by a subcutaneous preparation. Even a correct unit conversion would not resolve those differences.
Does the positive study settle the dosing question?
The fourteen-person 1987 study is relevant because it reports positive sleep and daytime-function findings. It belongs alongside the less encouraging controlled studies, rather than being omitted or presented as a universal response rate.
From the FormBlends catalog
DSIP (Delta Sleep-Inducing Peptide)
Restore deep, restorative delta wave sleep · From $179/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View DSIP (Delta Sleep-Inducing Peptide) →A small, short study can investigate whether a signal exists under its own conditions. It does not, by itself, establish a long-term regimen, a dose-escalation schedule or the result for a different route and formulation. The cited abstracts do not validate cycling five days on and two days off, a fixed bedtime injection interval, or combining DSIP with other peptides.
Reconstitution arithmetic answers a different question
Vial mass divided by final volume gives concentration. Concentration multiplied by a drawn volume gives the mass in that volume. That arithmetic can check a calculation, but it cannot determine the clinically appropriate amount, route or interval.
For the same reason, syringe markings do not establish a DSIP sleep protocol. A concentration table and an efficacy study provide different kinds of information. They should not be used interchangeably.
How to compare claims about DSIP sleep dosing
- Locate the named study rather than relying on an uncited “typical dose.”
- Check the route and whether the quantity is a mass or a molar amount per kilogram.
- Compare the actual sleep endpoint with the claim being made.
- Read the placebo comparison and the authors' interpretation alongside any positive result.
- Separate a short research regimen from claims about indefinite use or peptide stacks.
Frequently asked questions
Has DSIP been studied in people with insomnia?
Yes. The cited studies include controlled human insomnia research from 1987 and 1992, with mixed findings. Human research should not be confused with an established standard sleep dose.
Do those studies validate a 250-500 microgram bedtime injection?
The cited studies do not establish that subcutaneous regimen. The reported intravenous molar doses and study conditions are different.
Did every controlled study find better sleep?
No. One study reported substantial improvement; other studies judged the benefit limited. The endpoint and comparator matter.
Is a five-days-on, two-days-off cycle established?
That schedule is not established by the studies reviewed here.
Sources
- Monti and colleagues, Study of delta sleep-inducing peptide efficacy in improving sleep on short-term administration to chronic insomniacs, 1987
- Schneider-Helmert, Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia, 1987
- Bes and colleagues, Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients, 1992
Footer Disclaimers
Platform: FormBlends provides educational content for informational purposes only. Nothing on this page constitutes medical advice, diagnosis, or treatment. Consult a qualified healthcare professional before using any peptide or research compound.
Research Compound: DSIP is not approved by the FDA for any therapeutic indication. It is sold for research purposes only. It is not intended for human consumption except as part of a supervised clinical investigation.
Results: Individual results vary. The information presented reflects available published literature and community convention. Many claims about DSIP are based on low-quality or very old evidence. FormBlends does not guarantee any outcome.
Trademark: All product names and trademarks mentioned are the property of their respective owners. FormBlends is not affiliated with any peptide manufacturer or compounding pharmacy mentioned or implied in this article.
Ready when you are
DSIP (Delta Sleep-Inducing Peptide)
Restore deep, restorative delta wave sleep · From $179/mo · compounded by a licensed 503A pharmacy, dispensed only after provider review.
View DSIP (Delta Sleep-Inducing Peptide) →